Centrum Zdrowia i Urody MAXXMED

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)4 trials
• Parkinson disease3 trials
• Alzheimer disease1 trial
• Essential tremor1 trial

Phase

• Phase 37 trials
• Phase 22 trials

Status

• Completed7 trials
• Active, not recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Jazz Pharmaceuticals2 trials
• Amgen1 trial
• Amgen Inc.1 trial
• Cerevance1 trial
• Galderma R&D1 trial
• and 3 more

Running trials

• Active, not recruiting

  A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study

  2025-521772-57-00· Phase 3· Zambon Biotech S.A.· Source

Closed trials

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

  NCT05642442· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Amgen· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Completed

  Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206· Phase 3· Galderma R&D· Source